Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir

Author： de Niet A.   Takkenberg R.B.   Benayed R.   Riley-Gillis B.   Weegink C.J.   Zaaijer H.L.   Koot M.   Jansen P.L.M.   Beld M.G.H.M.   Lopatin U.   Reesink H.W.  

Publisher： Informa Healthcare

ISSN： 0036-5521

Source： Scandinavian Journal of Gastroenterology, Vol.47, Iss.4, 2012-04, pp. : 475-481

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B

By Papadopoulos Vasileios   Protopapas Andreas   Tsianos Epameinondas   Mimidis Konstantinos  

Scandinavian Journal of Gastroenterology, Vol. 44, Iss. 8, 2009-08 ,pp. : 1021-1022

Informa Healthcare

Access to resources Recommend Favorite

Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients

By  

Digestion, Vol. 84, Iss. 1, 2011-12 ,pp. : 23-28

Karger

Access to resources Recommend Favorite

Interferon Alfa-2b Alone or Combined with Recombinant Granulocyte-Macrophage Colony-Stimulating Factor as Treatment of Chronic Hepatitis C

By Grønbaek K.   Bygum Krarup H.   Ring-Larsen H.   Schaffalitzky De Muckadell O.   Møller A.   Schlichting P.   Vyberg M.  

Scandinavian Journal of Gastroenterology, Vol. 37, Iss. 7, 2002-07 ,pp. : 840-844

Informa Healthcare

Access to resources Recommend Favorite

Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b

By Deutsch Melanie   Manesis Emanuel   Hadziyannis Emilia   Vassilopoulos Dimitrios   Archimandritis Athanasios  

Scandinavian Journal of Gastroenterology, Vol. 42, Iss. 3, 2007-01 ,pp. : 408-409

Informa Healthcare

Access to resources Recommend Favorite

Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients

By Tsuge Masataka   Murakami Eisuke   Imamura Michio   Abe Hiromi   Miki Daiki   Hiraga Nobuhiko   Takahashi Shoichi   Ochi Hidenori   Nelson Hayes C.   Ginba Hiroyuki   Matsuyama Kazuhiro   Kawakami Hiroiku   Chayama Kazuaki  

Journal of Gastroenterology, Vol. 48, Iss. 10, 2013-10 ,pp. : 1188-1204

Springer Publishing Company

Access to resources Recommend Favorite